Alkermes (ALKS) Competitors $28.75 -0.25 (-0.86%) Closing price 07/3/2025 03:26 PM EasternExtended Trading$28.75 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALKS vs. BIIB, INCY, UTHR, NBIX, EXEL, BMRN, EXAS, RGEN, HALO, and MDGLShould you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Alkermes vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alkermes (NASDAQ:ALKS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations. Is ALKS or BIIB more profitable? Alkermes has a net margin of 23.30% compared to Biogen's net margin of 15.07%. Alkermes' return on equity of 27.52% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.30% 27.52% 17.98% Biogen 15.07%14.03%8.32% Which has higher valuation & earnings, ALKS or BIIB? Biogen has higher revenue and earnings than Alkermes. Biogen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B3.04$367.07M$2.0913.76Biogen$9.68B2.01$1.63B$10.1313.09 Does the media prefer ALKS or BIIB? In the previous week, Biogen had 19 more articles in the media than Alkermes. MarketBeat recorded 26 mentions for Biogen and 7 mentions for Alkermes. Alkermes' average media sentiment score of 1.12 beat Biogen's score of 0.91 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 16 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of ALKS or BIIB? 95.2% of Alkermes shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 4.4% of Alkermes shares are held by company insiders. Comparatively, 0.2% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, ALKS or BIIB? Alkermes has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Do analysts rate ALKS or BIIB? Alkermes presently has a consensus price target of $40.00, suggesting a potential upside of 39.13%. Biogen has a consensus price target of $188.48, suggesting a potential upside of 42.12%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83Biogen 0 Sell rating(s) 20 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.38 SummaryAlkermes beats Biogen on 11 of the 17 factors compared between the two stocks. Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALKS vs. The Competition Export to ExcelMetricAlkermesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.78B$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio13.7621.5627.4020.04Price / Sales3.04281.40419.65118.51Price / Cash10.9441.9536.6357.47Price / Book3.187.518.085.67Net Income$367.07M-$55.05M$3.16B$248.47M7 Day Performance-0.21%4.71%2.84%3.32%1 Month Performance-8.85%4.89%3.70%5.20%1 Year Performance18.65%5.82%35.31%21.35% Alkermes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALKSAlkermes4.913 of 5 stars$28.75-0.9%$40.00+39.1%+18.7%$4.78B$1.56B13.761,800News CoveragePositive NewsAnalyst RevisionBIIBBiogen4.943 of 5 stars$124.79-1.8%$188.19+50.8%-41.0%$18.29B$9.68B12.327,605INCYIncyte4.3982 of 5 stars$67.26-1.8%$74.53+10.8%+18.7%$13.02B$4.41B210.192,617UTHRUnited Therapeutics4.9955 of 5 stars$286.39-1.5%$393.08+37.3%-5.3%$12.92B$2.88B11.431,305Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.9355 of 5 stars$125.80-0.6%$162.00+28.8%-7.4%$12.45B$2.36B42.641,800EXELExelixis4.7494 of 5 stars$43.37+7.4%$41.00-5.5%+109.1%$11.83B$2.17B19.711,147Positive NewsAnalyst RevisionGap UpHigh Trading VolumeBMRNBioMarin Pharmaceutical4.9422 of 5 stars$54.08-1.7%$93.45+72.8%-29.3%$10.37B$2.95B20.103,040Analyst ForecastEXASExact Sciences4.9182 of 5 stars$52.54-0.9%$70.90+34.9%+22.3%$9.91B$2.76B-9.547,000Positive NewsAnalyst RevisionRGENRepligen4.817 of 5 stars$120.11+1.1%$173.25+44.2%+5.5%$6.75B$634.44M-266.911,778HALOHalozyme Therapeutics4.8184 of 5 stars$52.800.0%$61.90+17.2%+3.9%$6.51B$1.02B14.04390Analyst RevisionMDGLMadrigal Pharmaceuticals4.0777 of 5 stars$282.99-1.0%$420.63+48.6%+9.9%$6.28B$180.13M-15.6890 Related Companies and Tools Related Companies Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALKS) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
